Novo Nordisk
NVO
#16
Rank
A$772.99 B
Marketcap
$168.38
Share price
-1.53%
Change (1 day)
16.15%
Change (1 year)

Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.

Novo Nordisk (NVO) - Total debt

Total debt on the balance sheet as of September 2024 : A$13.43 Billion

According to Novo Nordisk's latest financial reports the company's total debt is A$13.43 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Novo Nordisk - Total debt on balance sheet (from 1996 to 2024)

Total debt by year

Year Total debt Change
2023-12-31A$5.87 B7.59%
2022-12-31A$5.45 B-2.49%
2021-12-31A$5.59 B151.34%
2020-12-31A$2.22 B131.9%
2019-12-31A$0.96 B757.13%
2018-12-31A$0.11 B-67.98%
2017-12-31A$0.34 B677.66%
2016-12-31A$44.98 M-79.16%
2015-12-31A$0.21 B50.22%
2014-12-31A$0.14 B221.99%
2013-12-31A$44.62 M-47.69%
2012-12-31A$85.31 M-41.13%
2011-12-31A$0.14 B-62.91%
2010-12-31A$0.39 B31.28%
2009-12-31A$0.29 B-51.83%
2008-12-31A$0.61 B102.17%
2007-12-31A$0.30 B-10.27%
2006-12-31A$0.34 B-41.52%
2005-12-31A$0.58 B45.08%
2004-12-31A$0.40 B1.85%
2003-12-31A$0.39 B13.01%
2002-12-31A$0.34 B-25.53%
2001-12-31A$0.46 B4.76%
2000-12-31A$0.44 B3.52%
1999-12-31A$0.43 B-32.31%
1998-12-31A$0.63 B-5.44%
1997-12-31A$0.67 B64.68%
1996-12-31A$0.40 B

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
A$104.88 B 680.55%๐Ÿ‡บ๐Ÿ‡ธ USA
A$48.99 B 264.63%๐Ÿ‡บ๐Ÿ‡ธ USA
A$80.92 B 502.25%๐Ÿ‡บ๐Ÿ‡ธ USA
A$40.08 B 198.32%๐Ÿ‡ซ๐Ÿ‡ท France